METHOD OF OBTAINING CELL LINES IN A PROTEIN-FREE MEDIUM AND CELL LINES THUS OBTAINED

Predmetni izum odnosi se na postupak oporavljanjastaničnih klonova sisavaca prilagođenih na medij bez seruma i proteina, a postupak uključuje dvo-stupanjski proces adaptacije na rast u tim uvjetima.Predmetni izum opisuje raspon kritične koncentracije proteina u kojem stanice moraju rasti da bi sedob...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SVIETA VITORES SARAZOLA, TAMMY BOGGIANO AYO, ROLANDO PEREZ RODRIGUEZ, LUIS ROJAS DEL CALVO, ADOLFO CASTILLO VITLLOCH
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Predmetni izum odnosi se na postupak oporavljanjastaničnih klonova sisavaca prilagođenih na medij bez seruma i proteina, a postupak uključuje dvo-stupanjski proces adaptacije na rast u tim uvjetima.Predmetni izum opisuje raspon kritične koncentracije proteina u kojem stanice moraju rasti da bi sedobio kapacitet za preživljenje u uvjetima bez seruma i proteina. Jednom kad su stanice uspjele rasti uz koncentracije iz kritičnog intervala, posljedična smanjenja koncentracija neće utjecati na njihovu vijabilnost niti na vrijeme udvostručenja stanica. Interval kritične koncentracije proteina je specifičan za pojedinu staničnu liniju. The invention relates to a method of obtaining mammal cells which are adapted to grow in a medium free of serum and proteins. The inventive method includes a process consisting of two adaptation steps comprising a critical protein concentration interval for each cell line. The invention also relates to mammal cell lines which grow in a stable manner in a medium free of serum and proteins over at least 40 generations. The invention further relates to clones which express anti-CD6 T1hT and EGFhR 3 antireceptor humanised antibodies and the anti-CD 3 T 3Q chimeric antibody as well as fragments of said antibodies.